SOPHiA GENETICS, which provides a data-driven SaaS platform for the healthcare industry, filed on Friday with the SEC to raise up to $100 million.
SOPHiA GENETICS provides a cloud-based software-as-a-service (SaaS) platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. In 2014, the company launched the first application of its platform to analyze NGS data for cancer diagnosis. As of March 31, 2021, it had approximately 240 applications used by healthcare providers, clinical and life sciences research laboratories and biopharmaceutical companies for precision medicine across oncology, rare diseases, infectious diseases, cardiology, neurology, metabolism and other disease areas.
The Saint-Sulpice, Switzerland-based company was founded in 2011 and booked $30 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol SOPH. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.